Pierre Frange1, Albert Faye2, Véronique Avettand-Fenoël3, Erianna Bellaton4, Diane Descamps5, Mathieu Angin6, Annie David6, Sophie Caillat-Zucman7, Gilles Peytavin8, Catherine Dollfus9, Jerome Le Chenadec10, Josiane Warszawski11, Christine Rouzioux3, Asier Sáez-Cirión12. 1. Laboratoire de Microbiologie Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; Unité d'Immunologie, Hématologie et Rhumatologie pédiatriques, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; EA7327, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: pierre.frange@aphp.fr. 2. Service de Pédiatrie Générale, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. 3. Laboratoire de Virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; EA7327, Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 4. Service d'Hématologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France. 5. IAME, INSERM UMR1137, Paris, France; Laboratoire de Virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France. 6. Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France. 7. Laboratoire d'Immunologie, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris, France; INSERM UMR1149, Paris, France. 8. IAME, INSERM UMR1137, Paris, France; Laboratoire de Pharma-Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France. 9. Service d'Hématologie et Oncologie pédiatriques, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Paris, France. 10. INSERM U1018, Université Paris Sud, Le Kremlin Bicêtre, France. 11. INSERM U1018, Université Paris Sud, Le Kremlin Bicêtre, France; Service d'Epidémiologie et de Santé publique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France. 12. Institut Pasteur, Unité HIV Inflammation et Persistance, Paris, France. Electronic address: asier.saez-cirion@pasteur.fr.
Abstract
BACKGROUND: Durable HIV-1 remission after interruption of combined antiretroviral therapy (ART) has been reported in some adults who started treatment during primary infection; however, whether long-term remission in vertically infected children is possible was unknown. We report a case of a young adult perinatally infected with HIV-1 with viral remission despite long-term treatment interruption. METHODS: The patient was identified in the ANRS EPF-CO10 paediatric cohort among 100 children infected with HIV perinatally who started ART before 6 months of age. HIV RNA viral load and CD4 cell counts were monitored from birth. Ultrasensitive HIV RNA, peripheral blood mononuclear cell (PBMC)-associated HIV DNA, HIV-specific T-cell responses (ie, production of cytokines and capacity to suppress HIV infection), reactivation of the CD4 cell reservoir (measured by p24 ELISA and HIV RNA in supernatants upon phytohaemagglutinin activation of purified CD4 cells), and plasma concentrations of antiretroviral drugs were assessed after 10 years of documented control off therapy. FINDINGS: The infant was born in 1996 to a woman with uncontrolled HIV-1 viraemia and received zidovudine-based prophylaxis for 6 weeks. HIV RNA and DNA were not detected 3 days and 14 days after birth. HIV DNA was detected at 4 weeks of age. HIV RNA reached 2·17× 10(6) copies per mL at 3 months of age and ART was started. HIV RNA was undetectable 1 month later. ART was discontinued by the family at some point between 5·8 and 6·8 years of age. HIV RNA was undetectable at 6·8 years of age and ART was not resumed. HIV RNA has remained below 50 copies per mL and CD4 cell counts stable through to 18·6 years of age. After 11·5 years of control off treatment, HIV RNA was below 4 copies per mL and HIV DNA was 2·2 log10 copies per 10(6) PBMCs. The HLA genotype showed homozygosity at several loci (A*2301-, B*1503/4101, C*0210/0802, DRB1*1101-, and DQB1*0602-). HIV-specific CD8 T-cell responses and T-cell activation were weak. INTERPRETATION: Findings from this case suggest that long-term HIV-1 remission is possible in perinatally infected children who receive treatment early, with characteristics similar to those reported in adult HIV post-treatment controllers. Further studies are needed to understand the mechanisms associated with HIV remission and whether early treatment of infected children might favour the conditions needed to achieve HIV control after treatment discontinuation. FUNDING: Agence de recherche ANRS (France Recherche Nord & Sud Sida-HIV Hépatites).
BACKGROUND: Durable HIV-1 remission after interruption of combined antiretroviral therapy (ART) has been reported in some adults who started treatment during primary infection; however, whether long-term remission in vertically infected children is possible was unknown. We report a case of a young adult perinatally infected with HIV-1 with viral remission despite long-term treatment interruption. METHODS: The patient was identified in the ANRS EPF-CO10 paediatric cohort among 100 children infected with HIV perinatally who started ART before 6 months of age. HIV RNA viral load and CD4 cell counts were monitored from birth. Ultrasensitive HIV RNA, peripheral blood mononuclear cell (PBMC)-associated HIV DNA, HIV-specific T-cell responses (ie, production of cytokines and capacity to suppress HIV infection), reactivation of the CD4 cell reservoir (measured by p24 ELISA and HIV RNA in supernatants upon phytohaemagglutinin activation of purified CD4 cells), and plasma concentrations of antiretroviral drugs were assessed after 10 years of documented control off therapy. FINDINGS: The infant was born in 1996 to a woman with uncontrolled HIV-1 viraemia and received zidovudine-based prophylaxis for 6 weeks. HIV RNA and DNA were not detected 3 days and 14 days after birth. HIV DNA was detected at 4 weeks of age. HIV RNA reached 2·17× 10(6) copies per mL at 3 months of age and ART was started. HIV RNA was undetectable 1 month later. ART was discontinued by the family at some point between 5·8 and 6·8 years of age. HIV RNA was undetectable at 6·8 years of age and ART was not resumed. HIV RNA has remained below 50 copies per mL and CD4 cell counts stable through to 18·6 years of age. After 11·5 years of control off treatment, HIV RNA was below 4 copies per mL and HIV DNA was 2·2 log10 copies per 10(6) PBMCs. The HLA genotype showed homozygosity at several loci (A*2301-, B*1503/4101, C*0210/0802, DRB1*1101-, and DQB1*0602-). HIV-specific CD8 T-cell responses and T-cell activation were weak. INTERPRETATION: Findings from this case suggest that long-term HIV-1 remission is possible in perinatally infected children who receive treatment early, with characteristics similar to those reported in adult HIV post-treatment controllers. Further studies are needed to understand the mechanisms associated with HIV remission and whether early treatment of infected children might favour the conditions needed to achieve HIV control after treatment discontinuation. FUNDING: Agence de recherche ANRS (France Recherche Nord & Sud Sida-HIV Hépatites).
Authors: Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Radwa Sharaf; Guinevere Q Lee; Xiaoming Sun; Behzad Etemad; Layla M Aboukhater; Zixin Hu; Zabrina L Brumme; Evgenia Aga; Ronald J Bosch; Ying Wen; Golnaz Namazi; Ce Gao; Edward P Acosta; Rajesh T Gandhi; Jeffrey M Jacobson; Daniel Skiest; David M Margolis; Ronald Mitsuyasu; Paul Volberding; Elizabeth Connick; Daniel R Kuritzkes; Michael M Lederman; Xu G Yu; Mathias Lichterfeld; Jonathan Z Li Journal: J Clin Invest Date: 2018-08-20 Impact factor: 14.808
Authors: Steven G Deeks; Sharon R Lewin; Anna Laura Ross; Jintanat Ananworanich; Monsef Benkirane; Paula Cannon; Nicolas Chomont; Daniel Douek; Jeffrey D Lifson; Ying-Ru Lo; Daniel Kuritzkes; David Margolis; John Mellors; Deborah Persaud; Joseph D Tucker; Françoise Barre-Sinoussi; Galit Alter; Judith Auerbach; Brigitte Autran; Dan H Barouch; Georg Behrens; Marina Cavazzana; Zhiwei Chen; Éric A Cohen; Giulio Maria Corbelli; Serge Eholié; Nir Eyal; Sarah Fidler; Laurindo Garcia; Cynthia Grossman; Gail Henderson; Timothy J Henrich; Richard Jefferys; Hans-Peter Kiem; Joseph McCune; Keymanthri Moodley; Peter A Newman; Monique Nijhuis; Moses Supercharger Nsubuga; Melanie Ott; Sarah Palmer; Douglas Richman; Asier Saez-Cirion; Matthew Sharp; Janet Siliciano; Guido Silvestri; Jerome Singh; Bruno Spire; Jeffrey Taylor; Martin Tolstrup; Susana Valente; Jan van Lunzen; Rochelle Walensky; Ira Wilson; Jerome Zack Journal: Nat Med Date: 2016-07-11 Impact factor: 53.440
Authors: Mary Grace Katusiime; Elias K Halvas; Imogen Wright; Kevin Joseph; Michael J Bale; Bronwyn Kirby-McCullough; Susan Engelbrecht; Wei Shao; Wei-Shau Hu; Mark F Cotton; John W Mellors; Mary F Kearney; Gert U van Zyl Journal: J Virol Date: 2020-01-31 Impact factor: 5.103